查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403409

到 2030 年乳癌诊断市场预测：按产品、类型、应用、最终用户和地区进行的全球分析

Breast Cancer Diagnostics Market Forecasts to 2030 - Global Analysis By Product, Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球乳癌诊断市场规模将达到 47.5 亿美元，预计到 2030 年将达到 89.2 亿美元，预测期内复合年增长率为 9.4%。

乳癌诊断对于早期发现和有效的治疗计划至关重要。早期发现可以及时干预，提高存活率并减少积极治疗的需要。诊断剂可以帮助表征肿瘤类型、指导个体化治疗并监测治疗反应。它使医疗保健专业人员能够根据患者的个别需求量身定制干预措施并优化结果。

据美国癌症协会称，2021 年，仅美国就有约 281,550 例乳腺癌新诊断和 49,290 例相关死亡。

乳癌发生率上升

乳癌盛行率的上升是乳癌诊断的重要催化剂。随着全球病例数量的增加，对先进诊断技术和筛检方法的需求也在增加。早期检测对于有效治疗至关重要，并且正在推动乳房X光摄影、分子诊断和切片检查等诊断工具的创新。对准确、及时的乳癌诊断的需求激增是推动市场扩张的关键因素。

过度诊断和误报的风险

过度诊断或假阳性是癌症存在的错误指示，但实际上癌症并不存在。这可能会给患者带来不必要的情绪困扰、焦虑和恐惧。此外，它们经常引发切片检查等侵入性手术，使患者面临潜在的身体伤害和不适。生活在对癌症的恐惧中的心理负担和额外医学检查的经济负担可能会影响患者的整体健康。

整合人工智慧和机器学习

人工智慧 (AI) 和机器学习 (ML) 在乳癌诊断中的整合透过分析复杂的资料模式、支援早期检测和个体化治疗策略，提高了诊断过程的准确性和效率。人工智慧和机器学习使医疗保健专业人员能够做出更资讯的决策，从而改善患者的治疗结果。这项进步不仅有望彻底改变诊断能力，还将促进市场创新并提高准确性和有效性，以解决全球最普遍和最关键的健康挑战之一。

诊断费用高

乳癌诊断需要先进的技术，例如乳房X光摄影、MRI和基因检测，这些技术的开发、维护和操作成本高昂。这些诊断工具的复杂性加上严格的品质标准导致了昂贵的程序。这种财务障碍限制了及时发现和治疗，并对患者的治疗结果产生负面影响。因此，市场面临着实现广泛普及、改善患者治疗结果以及解决乳癌对公共卫生的广泛影响的挑战。

COVID-19 的影响

COVID-19 的疫情对市场产生了重大影响。常规筛检的延迟、患者就诊的减少以及医疗资源紧张导致乳癌确诊病例减少。供应链和医疗保健服务的中断也影响市场的成长。然而，意识的提高和远端医疗和人工智慧诊断等技术进步正在推动乳癌大流行后的復苏并重塑乳癌诊断的格局。

预计切片检查市场在预测期内将是最大的

切片检查领域预计将经历良好的成长。切片检查是确认恶性的重要步骤。从受影响的区域取出一小块组织样本并在显微镜下检查。切片检查结果指南治疗决策，并帮助医疗保健专业人员为诊断为乳癌的患者提供有效的治疗和干预措施。早期和准确的切片检查结果对于确保及时和适当的乳癌治疗至关重要。

预计热成像产业在预测期内将呈现最高的复合年增长率。

预计热成像领域在预测期内将以最高的复合年增长率成长。乳癌诊断中的热成像技术使用红外线影像来检测乳房组织的热模式和潜在异常。热成像是一种非侵入性、无辐射的技术，可突显与血流和细胞活动相关的温度变化。非接触和无压力的性质使体验更加舒适，并且是传统诊断工具的宝贵辅助。

比最大的地区

由于意识的提高、医疗保健支出的增加以及诊断技术的进步，预计亚太地区将在预测期内占据最大的市场占有率。亚太地区是 GE Healthcare、Abbott Laboratories、Siemens Healthineers 和 Roche Diagnostics 等主要企业的所在地。这些公司提供各种诊断技术。由于亚太地区患者人数不断增长以及政府为提高癌症意识和筛检所做的努力，预计该市场将继续呈上升趋势。

复合年增长率最高的地区：

预计北美在预测期内的复合年增长率最高。在北美，美国占有最大的市场占有率。该地区拥有多个市场参与者，包括 Bio-Rad Laboratories、Agendia、Genomic Health 和 Myriad Genetics。这些主要企业正在采取併购、联盟等策略来获得更大的市场占有率。乳癌是大多数美国国家最常诊断的癌症。乳癌盛行率的上升，加上北美医疗保健基础设施的开拓，预计将推动整体市场的成长。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球乳癌诊断市场：副产品

  • 以仪器为基础的产品
  • 基于平台的产品

第六章全球乳癌诊断市场：按类型

  • 切片检查
    • 针吸切片
    • 手术切片检查
  • 影像
  • 验血
    • 生物标记测试
    • 循环性肿瘤细胞(CTC) 检测
  • 基因组测试
    • 基因表现
    • 下一代定序（NGS）
  • 核医学诊断
    • 前哨淋巴结活检
    • 正子断层扫描 (PET)
  • 组织病理学
  • 其他类型

第七章全球乳癌诊断市场：依应用分类

  • 筛检
    • 乳房X光照相术
    • 乳房自我检测（BSE）
    • 临床乳房检查 (CBE)
    • 分子乳房影像 (MBI)
    • 乳腺超音波检查
  • 诊断影像
    • X射线
    • 磁振造影(MRI)
    • 电脑断层扫描 (CT) 扫描
    • 超音波
    • 分子成像技术
  • 热成像
  • 其他用途

第八章全球乳癌诊断市场：依最终用户分类

  • 医院和诊所
  • 诊断中心和医学实验室
  • 其他最终用户

第九章全球乳癌诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Hologic Inc
  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Abbott Laboratories
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • PerkinElmer Inc.
  • Agilent Technologies
  • Becton, Dickinson and Company（BD）
  • Myriad Genetics Inc.
  • Sysmex Corporation
  • NanoString Technologies
  • Genomic Health
  • Illumina Inc.
  • Bio-Rad Laboratories
  • Sienna Cancer Diagnostics
  • Cepheid
  • Invivo Corporation
  • Aurora Diagnostics
Product Code: SMRC24634

According to Stratistics MRC, the Global Breast Cancer Diagnostics Market is accounted for $4.75 billion in 2023 and is expected to reach $8.92 billion by 2030 growing at a CAGR of 9.4% during the forecast period. Breast cancer diagnostics are crucial for early detection and effective treatment planning. Early identification enables timely intervention, improving survival rates and reducing the need for aggressive treatments. Diagnostics aid in characterizing tumor types, guiding personalized therapies, and monitoring treatment response. They empower healthcare professionals to tailor interventions to individual patient needs, optimizing outcomes.

According to the American Cancer Society, it is estimated that approximately 281,550 new cases of breast cancer will be diagnosed in 2021, with an expected 49,290 related deaths in the U.S. alone.

Market Dynamics:

Driver:

Rising incidence of breast cancer

The escalating prevalence of breast cancer is a key catalyst for the breast cancer diagnostics. With a rising number of cases globally, there is an increasing demand for advanced diagnostic technologies and screening methods. Early detection is crucial for effective treatment, driving innovation in diagnostic tools such as mammography, molecular diagnostics, and biopsy. This surge in demand for accurate and timely breast cancer diagnosis is a significant factor fueling the expansion of the market.

Restraint:

Risk of overdiagnosis & false positives

Overdiagnosis and false positive result erroneously indicates the presence of cancer when it is not actually present. This can lead to unnecessary emotional distress, anxiety, and fear for the patient. Moreover, it often triggers further invasive procedures such as biopsies, exposing individuals to potential physical harm and discomfort. The psychological toll of living with the fear of cancer and the financial burden of additional medical tests can impact a patient's overall well-being.

Opportunity:

Integration of artificial intelligence & machine learning

The integration of artificial intelligence (AI) and machine learning (ML) in breast cancer diagnostics enhance the accuracy and efficiency of diagnostic processes by analyzing complex data patterns, aiding in early detection, and personalized treatment strategies. AI and ML empower healthcare professionals to make more informed decisions, leading to improved patient outcomes. This advancement not only revolutionizes diagnostic capabilities but also fosters innovation in the market, promising enhanced precision and effectiveness in addressing one of the most prevalent and critical health challenges worldwide.

Threat:

High cost of diagnostic procedures

Breast Cancer Diagnostics procedures involve advanced technologies such as mammography, MRI, and genetic testing, which incur high development, maintenance, and operational expenses. The intricate nature of these diagnostic tools, coupled with stringent quality standards, results in expensive procedures. This financial barrier limits timely detection and treatment, negatively impacting patient outcomes. As a result, the market faces challenges in achieving widespread adoption, improving patient outcomes, and addressing the broader public health impact of breast cancer.

COVID-19 Impact

The COVID-19 pandemic has significantly impacted the market. Delays in routine screenings, reduced patient visits, and strained healthcare resources have led to a decline in the diagnosis of breast cancer cases. Disruptions in supply chains and healthcare services have also affected the market's growth. However, increased awareness and technological advancements, such as telemedicine and AI-driven diagnostics, have driven recovery and reshaped the landscape for breast cancer diagnostics in the post-pandemic era.

The biopsy segment is expected to be the largest during the forecast period

The biopsy segment is estimated to have a lucrative growth. Biopsy is a crucial procedure for confirming malignancy. It involves extracting a small tissue sample from the affected area for examination under a microscope. Biopsy results guide treatment decisions, helping healthcare professionals tailor effective therapies and interventions for patients diagnosed with breast cancer. Early and accurate biopsy results are pivotal in ensuring timely and appropriate management of breast cancer.

The thermography segment is expected to have the highest CAGR during the forecast period

The thermography segment is anticipated to witness the highest CAGR growth during the forecast period. Thermography in breast cancer diagnostics involves using infrared imaging to detect heat patterns and potential abnormalities in breast tissue. It is a non-invasive and radiation-free technique that highlights variations in temperature associated with blood flow and cellular activity. Its non-contact nature and lack of compression contribute to a more comfortable experience, making it a valuable adjunct to traditional diagnostic tools.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the rising awareness, increased healthcare expenditure, and advancements in diagnostic technologies. It has the presence of top most players namely GE Healthcare, Abbott Laboratories, Siemens Healthineers and Roche Diagnostics. These companies often offer a diverse range of diagnostic technologies. The market is expected to continue its upward trajectory, driven by a growing patient population and government initiatives promoting cancer awareness and screening in the Asia-Pacific region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. The U.S. held the largest market share of the market in North America. The region is home to several market players including Bio-Rad Laboratories, Agendia, Genomic Health and Myriad Genetics. These key companies are adopting strategies such as mergers and acquisitions and partnerships, to acquire a larger market share. Breast cancer is the most commonly diagnosed cancer in most American countries. The rising prevalence of breast cancer, coupled with the development of healthcare infrastructure in North America, is expected to drive overall market growth.

Key players in the market:

Some of the key players profiled in the Breast Cancer Diagnostics Market include Hologic Inc, GE Healthcare, Siemens Healthineers, Philips Healthcare, Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, PerkinElmer Inc., Agilent Technologies, Becton, Dickinson and Company (BD), Myriad Genetics Inc., Sysmex Corporation, NanoString Technologies, Genomic Health, Illumina Inc., Bio-Rad Laboratories, Sienna Cancer Diagnostics, Cepheid, Invivo Corporation and Aurora Diagnostics.

Key Developments:

In December 2023, GE HealthCare released a new, all-in-one platform of artificial intelligence (AI) apps to support clinicians with breast cancer detection and improved workflow productivity called MyBreastAI Suite.

In May 2023, Pfizer and Thermo Fisher Scientific Inc. have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.

Products Covered:

  • Instrument-based Products
  • Platform-based Products

Types Covered:

  • Biopsy
  • Imaging
  • Blood Tests
  • Genomic Tests
  • Nuclear Medicine Diagnostics
  • Histopathology
  • Other Types

Applications Covered:

  • Screening
  • Diagnostic Imaging
  • Thermography
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Centers & Medical Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Instrument-based Products
  • 5.3 Platform-based Products

6 Global Breast Cancer Diagnostics Market, By Type

  • 6.1 Introduction
  • 6.2 Biopsy
    • 6.2.1 Needle Biopsy
    • 6.2.2 Surgical Biopsy
  • 6.3 Imaging
  • 6.4 Blood Tests
    • 6.4.1 Biomarker Testing
    • 6.4.2 Circulating Tumor Cells (CTCs) Testing
  • 6.5 Genomic Tests
    • 6.5.1 Gene Expression Profiling
    • 6.5.2 Next-Generation Sequencing (NGS)
  • 6.6 Nuclear Medicine Diagnostics
    • 6.6.1 Sentinel Lymph Node Biopsy
    • 6.6.2 Positron Emission Tomography (PET)
  • 6.7 Histopathology
  • 6.8 Other Types

7 Global Breast Cancer Diagnostics Market, By Application

  • 7.1 Introduction
  • 7.2 Screening
    • 7.2.1 Mammography
    • 7.2.2 Breast Self-Examination (BSE)
    • 7.2.3 Clinical Breast Examination (CBE)
    • 7.2.4 Molecular Breast Imaging (MBI)
    • 7.2.5 Breast Ultrasound
  • 7.3 Diagnostic Imaging
    • 7.3.1 X-ray
    • 7.3.2 Magnetic Resonance Imaging (MRI)
    • 7.3.3 Computed Tomography (CT) Scan
    • 7.3.4 Ultrasound
    • 7.3.5 Molecular Imaging Techniques
  • 7.4 Thermography
  • 7.5 Other Applications

8 Global Breast Cancer Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Centers & Medical Laboratories
  • 8.4 Other End Users

9 Global Breast Cancer Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Hologic Inc
  • 11.2 GE Healthcare
  • 11.3 Siemens Healthineers
  • 11.4 Philips Healthcare
  • 11.5 Abbott Laboratories
  • 11.6 Roche Diagnostics
  • 11.7 Thermo Fisher Scientific
  • 11.8 PerkinElmer Inc.
  • 11.9 Agilent Technologies
  • 11.10 Becton, Dickinson and Company (BD)
  • 11.11 Myriad Genetics Inc.
  • 11.12 Sysmex Corporation
  • 11.13 NanoString Technologies
  • 11.14 Genomic Health
  • 11.15 Illumina Inc.
  • 11.16 Bio-Rad Laboratories
  • 11.17 Sienna Cancer Diagnostics
  • 11.18 Cepheid
  • 11.19 Invivo Corporation
  • 11.20 Aurora Diagnostics

List of Tables

  • Table 1 Global Breast Cancer Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Breast Cancer Diagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Breast Cancer Diagnostics Market Outlook, By Instrument-based Products (2021-2030) ($MN)
  • Table 4 Global Breast Cancer Diagnostics Market Outlook, By Platform-based Products (2021-2030) ($MN)
  • Table 5 Global Breast Cancer Diagnostics Market Outlook, By Type (2021-2030) ($MN)
  • Table 6 Global Breast Cancer Diagnostics Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 7 Global Breast Cancer Diagnostics Market Outlook, By Needle Biopsy (2021-2030) ($MN)
  • Table 8 Global Breast Cancer Diagnostics Market Outlook, By Surgical Biopsy (2021-2030) ($MN)
  • Table 9 Global Breast Cancer Diagnostics Market Outlook, By Imaging (2021-2030) ($MN)
  • Table 10 Global Breast Cancer Diagnostics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 11 Global Breast Cancer Diagnostics Market Outlook, By Biomarker Testing (2021-2030) ($MN)
  • Table 12 Global Breast Cancer Diagnostics Market Outlook, By Circulating Tumor Cells (CTCs) Testing (2021-2030) ($MN)
  • Table 13 Global Breast Cancer Diagnostics Market Outlook, By Genomic Tests (2021-2030) ($MN)
  • Table 14 Global Breast Cancer Diagnostics Market Outlook, By Gene Expression Profiling (2021-2030) ($MN)
  • Table 15 Global Breast Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 16 Global Breast Cancer Diagnostics Market Outlook, By Nuclear Medicine Diagnostics (2021-2030) ($MN)
  • Table 17 Global Breast Cancer Diagnostics Market Outlook, By Sentinel Lymph Node Biopsy (2021-2030) ($MN)
  • Table 18 Global Breast Cancer Diagnostics Market Outlook, By Positron Emission Tomography (PET) (2021-2030) ($MN)
  • Table 19 Global Breast Cancer Diagnostics Market Outlook, By Histopathology (2021-2030) ($MN)
  • Table 20 Global Breast Cancer Diagnostics Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 21 Global Breast Cancer Diagnostics Market Outlook, By Application (2021-2030) ($MN)
  • Table 22 Global Breast Cancer Diagnostics Market Outlook, By Screening (2021-2030) ($MN)
  • Table 23 Global Breast Cancer Diagnostics Market Outlook, By Mammography (2021-2030) ($MN)
  • Table 24 Global Breast Cancer Diagnostics Market Outlook, By Breast Self-Examination (BSE) (2021-2030) ($MN)
  • Table 25 Global Breast Cancer Diagnostics Market Outlook, By Clinical Breast Examination (CBE) (2021-2030) ($MN)
  • Table 26 Global Breast Cancer Diagnostics Market Outlook, By Molecular Breast Imaging (MBI) (2021-2030) ($MN)
  • Table 27 Global Breast Cancer Diagnostics Market Outlook, By Breast Ultrasound (2021-2030) ($MN)
  • Table 28 Global Breast Cancer Diagnostics Market Outlook, By Diagnostic Imaging (2021-2030) ($MN)
  • Table 29 Global Breast Cancer Diagnostics Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 30 Global Breast Cancer Diagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) (2021-2030) ($MN)
  • Table 31 Global Breast Cancer Diagnostics Market Outlook, By Computed Tomography (CT) Scan (2021-2030) ($MN)
  • Table 32 Global Breast Cancer Diagnostics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 33 Global Breast Cancer Diagnostics Market Outlook, By Molecular Imaging Techniques (2021-2030) ($MN)
  • Table 34 Global Breast Cancer Diagnostics Market Outlook, By Thermography (2021-2030) ($MN)
  • Table 35 Global Breast Cancer Diagnostics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 36 Global Breast Cancer Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 Global Breast Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 38 Global Breast Cancer Diagnostics Market Outlook, By Diagnostic Centers & Medical Laboratories (2021-2030) ($MN)
  • Table 39 Global Breast Cancer Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.